RBC Capital lowered the firm’s price target on PTC Therapeutics (PTCT) to $57 from $65 and keeps an Outperform rating on the shares after data from the company’s phase 2 PIVOT-HD study of PTC518 in stage 2 and stage 3 Huntington’s disease patients. The firm acknowledges some possible signals for ‘518 in the pre-defined, mechanistically rational earlier-stage population, good safety, which is reassuring, and understandable limitations with HD heterogeneity and to clinical and biomarker assays. Still, RBC believes the entirety of the results just does not look quite as promising as the earlier cut. While it had not expected statistical significance clinical score benefits and always expected PTC would need some phase 3 results to satisfy FDA, today’s more mixed data may push regulators to want more from phase 3 prior to approval, and adds risk to future studies, the firm argues.

Protect Your Portfolio Against Market Uncertainty

Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on PTCT:

Disclaimer & DisclosureReport an Issue

PTC data ‘brought more confusion than answers,’ says Citi PTC Therapeutics Reports Positive Phase 2 Study Results PTC Therapeutics’ PTC518 achieves primary endpoint in Phase 2 Huntington’s study Is PTCT a Buy, Before Earnings? PTC Therapeutics: Strategic Advancements and Market Opportunities Drive Buy Rating

View Comments